Qute smoking join in the mission against smoking and Gutkha . Save future of Childrens

Tobaco is one of the herb which has paralised mankind .

If you are smoking ,chewing , or consuming tobaco in any form , then keep in mind that you are poisoning your brain.
Effect of smoking on our Brain
It first increase the stimulation in brain , it gives you , feeling of wellbeing , but after smoking after an hour or two  , tobaco exactly works in reverse manner....It will bring depression in your brain.....It will make you less confident.....It will make you forget many important tings which are essential to become sucessful in Job , Bussiness , and personal life too.

Why there is feeling of wellbeing?
*Tobaco contains a alcoloid called as Nicotine ...It mimiks all activities of neuro trasmeter in brain like noradrenaline and adrenaline.
This brings about initial stimulation in our brain.

Why It Gives Dipression after few hours of smoking.
As this is not a true neuro trasmeter , our body develops a feed back mechanism to counteract its stimulation activty .
This leads to state of dipression after some time , where person is not able to do his work normaly.
This is where dwonfall starts for mankind.
No one understand that , the cigarte that they are smoking is giving pleaure for a munite , and making your brain a less functional , than before smoking.

The same things happen when tobaco is consumed in any form , like gutkha , pan etc.

This effect is causes loss to an individual .
He becomes unsucessful in his carrier , in his life , apparently he may be sucessful but really if you ask a smoking guy , they will tel you exactly the same thing that i am writing here.

This cause loss to our nation and mankind , families .

I have decided to start a drive to educate peoples and ask every one to stay away from smoking , gutkha , and tobaco.

I have a dream ,  i want to see a world where no one will make use of tobaco , for smoking cigarete , chewing , and as a gutkha.

Realy gutkha has become a curce for india , every college going kid is traped in to the habit of chewing gutkah amd , cigarete smoking.

We anounce that we have a mission , to educate , peoples for living healthy life , where there is no place for smoking , and Gutkha.

We will help peoples to quite smoking.Click Here!
We will educate students for staying away from Gutkha.

FDA Marks 100th HIV/AIDS Drug Authorized for Purchase Under PEPFAR

The U.S. Department of Health and Human Services (HHS) today marked today marked the recent approval of the 100th antiretroviral drug in association with the President’s Emergency Plan for AIDS Relief (PEPFAR), aimed at the prevention, treatment, and care of people infected with and affected by HIV/AIDS worldwide.
The PEPFAR program is a cooperative effort that involves the Food and Drug Administration (FDA) and other HHS agencies, the State Department’s Office of the U.S. Global AIDS Coordinator, U.S. Department of Defense, other federal agencies, host country governments, and many other international partners.
“This milestone exemplifies the dedication, caring, and hard work of all who strive to better the lives of those infected with or affected by HIV/AIDS,” said HHS Secretary Kathleen Sebelius.
To date, more than 100 products that have been assessed by the FDA and either fully or tentatively approved in association with the PEPFAR program. Of these, 29 have been new products and 71 have been generic copies of previously authorized antiretroviral products in the United States. Twenty-two of these new products are new combinations or regimens that have not previously been authorized in the United States. In addition, there are seven new pediatric products considered innovative for patients in developing economies.
“As we recognize the 100th product authorized in this program, it is estimated that FDA’s actions are allowing PEPFAR to spend $150 million more each year on patient access to care,” FDA Commissioner Margaret A. Hamburg, M.D., told those attending an event marking the approval at the Pan American Health Organization (PAHO) headquarters in Washington, D.C. “I look forward to developing and expanding FDA’s international collaborations.”
As of Sept. 30, 2008, the most recent figure available, PEPFAR supported life-saving antiretroviral treatment for more than 2.1 million men, women, and children living with HIV/AIDS. In fiscal year 2008, PEPFAR provided nearly $1.6 billion in support of treatment programs, including antiretroviral drugs and services.
“PEPFAR is committed to supporting partner countries to build and maintain sustainable procurement and supply chain systems,” said U.S. Global AIDS Coordinator Eric Goosby.
Drug products used in PEPFAR receive a “tentative approval” and cannot be approved for marketing in the United States because of existing patents and marketing exclusivity. However, these products meet all the FDA’s manufacturing quality, clinical safety, and efficacy requirements to produce them using the same standards as required for marketing in this country.
FDA performs all of its reviews of applications received in association with the PEPFAR on an expedited basis. After receiving approval or tentative approval from FDA under this expedited process, a generic anti-retroviral passes quickly on to the pre-qualification list maintained by the Secretariat of the World Health Organization (WHO), because of a confidentiality agreement that allows FDA to share data from its evaluations with the WHO team in Geneva.
“Improving access to good quality medicinal products is a core objective of public health efforts and one with a direct and measurable impact on health,” said Margaret Chan, M.D., director-general of WHO.
The goal of PEPFAR is to work with host nations to support treatment of at least 3 million people, prevention of 12 million new infections, and providing care for more than 12 million HIV-infected and affected people by 2013. In addition, PEPFAR will support training of at least 140,000 health care workers in HIV/AIDS prevention, treatment, and care.
“We need to urgently and actively implement strategies to promote greater affordability of both first and second line HIV/AIDS antiretrovirals,” said Mirta Roses, M.D., director of PAHO, an international public health agency that works to improve health and living standards in the Americas. “PEPFAR has made a tremendous difference in the health of disadvantaged people.”
For more information
PEPFAR Web site

AIDS vaccine development , combination of Sanofi-Pasteur's ALVAC canary and HIV vaccine AIDSVAX , Gives promising results for future development

AIDS vaccine resrarch combination of Sanofi-Pasteur's ALVAC canary and HIV vaccine AIDSVAX , Gives promising results for future development .
Results of study conducted in Thiland are very promising and there are lots of  hope become alive after this finding , for HIV vaccine research , as so far no vaccine has so much sucessful in preventing HIV infection , scientists conducted the trials said actual commercial production would be possible in coming five years.


The AIDS vaccine which was studied is a combination of Sanofi-Pasteur's ALVAC canary and HIV vaccine AIDSVAX of San Francisco company called VaxGen and now owned by the nonprofit Global Solutions for Infectious Diseases.
The trial was conducted in group of 16402 Voletiers the risk of infection had been cut by 31.2 per cent
Dr Anthony Fauci of the US National Institute of Allergy and Infectious Diseases, which helped pay for the study. said "Myself, like others, did not think there was a very high chance that this would give any degree of efficacy,"


"But nonetheless, we went ahead with the trial and it was controversial to go ahead with it."


That is the mind of scientist , who will never give up till he finds the solution...Keep it up Sir.

ALVAC is a genetically engineered canarypox virus that has spliced into it synthetic versions of three HIV genes.

AIDSVAX is made using two versions of one HIV gene, one from the B subtype and one from the E subtype.

This is a best logic , and method to combine all possible antigen , which will synergisticaly act to produce maximum protection against incoming infection.

The volunteers participated in this trial were given six immunisations over six months, four with ALVAC and two with AIDSVAX.

(I found all over that peoples have discribed the FAILED vaccine , to discribe AIDSVAX. as it has failed to HIV prevent infection in its individual trial , but i say that was a win for this science , and mankind , we fail and learn where we lacked , and now the combination results are impressive  )   

The results were published on 24-09-09 , this is a big step towards the actual development of an effective vaccine which will provide life saving treatment to this world , against HIV infection in years to come.